Skip to main content
. 2017 Feb 22;2017:3414910. doi: 10.1155/2017/3414910

Table 3.

CTC positivity (number of cases and percentage) by ScreenCell stratified according to clinical settings and timepoints.

Clinical setting CTC+ (%) at baseline
(T0)
CTC+ (%) after the 1st cycle of therapy
(T1)
CTC+ (%) after the 2nd cycle of therapy
(T2)
M 0 11/13 (84.6%) 4/10 (40.0%) 12/14 (85.7%)
M + 32/38 (84.2%) 27/30 (90.0%) 16/17 (94.1%)
M1 22/27 (81.5%) 20/22 (90.9%) 16/17 (94.1%)
M2 10/11 (90.9%) 7/8 (87.5%)
Total 43/51 (84.3%) 31/40 (77.5%) 28/31 (90.3%)